Linagliptin effective in some patients with type 2 diabetes, inhaled insulin improves glucose control in type 1 diabetes

Among the top stories in endocrinology this week was a study that found linagliptin was effective and safe in patients with type 2 diabetes that also have kidney disease and CVD, a report that concluded that empagliflozin added to the life expectancy of patients with diabetes and CVD and another study that found that inhaled insulin led to better glucose control in patients with type 1 diabetes.

Other popular stories included findings that mindfulness might mediate some of the symptoms associated with menopause and new information regarding a possible app for automated insulin delivery devices. – by Janel Miller

CARMELINA: Linagliptin safe, effective in type 2 diabetes with CVD, kidney disease

Among adults with type 2 diabetes, established CVD and/or chronic kidney disease, the DPP-IV inhibitor linagliptin demonstrated CV safety and a neutral effect for hospitalization for heart failure and kidney outcomes vs. placebo, according to findings from the CARMELINA trial presented at the European Association for the Study of Diabetes annual meeting. Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *